Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acasunlimab alone or with pembrolizumab in relapsed/refractory metastatic non-small cell lung cancer
NL-OMON59150Phase 2Completed
- Sponsor
- Genmab
- Start
- Dec 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of acasunlimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Genmab. Primary endpoint: Objective response rate. Started Dec 2022; status: completed.
02
Drugs
acasunlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59150.